Lilly Acquires Centessa for $6.3B to Boost Sleep Disorder Pipeline

Eli Lilly and Company is making a significant strategic move into the sleep disorder therapeutics arena, announcing a definitive agreement to acquire Centessa Pharmaceuticals for an upfront sum of $6.3 billion. This substantial investment underscores Lilly's commitment to expanding its neuroscience pipeline, with a particular focus on novel treatments for conditions affecting the sleep-wake cycle. The deal could potentially reach $7.8 billion with the inclusion of contingent value rights tied to regulatory achievements.

The acquisition centers on Centessa's promising portfolio of orexin receptor 2 (OX2R) agonists. These compounds are designed to directly influence the biological pathways governing wakefulness, offering a new therapeutic avenue for patients suffering from excessive daytime sleepiness and related neurological impairments. The market for sleep disorder treatments is substantial and growing, driven by increasing awareness and diagnosis rates of conditions like narcolepsy and idiopathic hypersomnia. Industry analysts project continued expansion in this segment, making Lilly's move a timely one.

Centessa's lead asset, cleminorexton (formerly ORX750), has demonstrated encouraging early-stage clinical results in trials targeting narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Beyond this lead candidate, Centessa possesses a pipeline of additional assets in various stages of development, with potential applications extending to broader neurological, neurodegenerative, and neuropsychiatric indications. This depth and breadth of Centessa's research significantly bolsters Lilly's existing neuroscience capabilities.

Under the terms of the transaction, shareholders of Centessa Pharmaceuticals will receive $38.00 in cash per share, along with a contingent value right (CVR) that could yield an additional $9.00 per share. This CVR is contingent upon the successful achievement of specific U.S. Food and Drug Administration (FDA) approval milestones for treatments related to narcolepsy type 2, idiopathic hypersomnia, and other specified indications within defined timelines. The upfront offer represents a notable premium, approximately 40.5%, above Centessa's 30-day volume-weighted average share price prior to the announcement.

The transaction has received unanimous approval from the boards of directors of both companies. Its completion is anticipated in the third quarter, subject to customary closing conditions, including shareholder consent, court sanction in England and Wales, and regulatory approvals. Crucially, the deal has garnered strong support from key Centessa shareholders, including affiliates of Medicxi Ventures, Index Ventures, and General Atlantic, who collectively hold approximately 24.1% of the company's outstanding shares, signaling confidence in the strategic rationale of the acquisition.

Upon closing, Lilly intends to integrate Centessa's scientific expertise and development programs into its extensive global research, clinical development, and commercialization infrastructure. This integration aims to expedite the advancement of orexin-based therapies, ultimately broadening the treatment options available for individuals grappling with sleep-wake disorders. The combined entity is positioned to accelerate innovation in a therapeutic area with significant unmet patient needs.